JP2005500854A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005500854A5 JP2005500854A5 JP2003523683A JP2003523683A JP2005500854A5 JP 2005500854 A5 JP2005500854 A5 JP 2005500854A5 JP 2003523683 A JP2003523683 A JP 2003523683A JP 2003523683 A JP2003523683 A JP 2003523683A JP 2005500854 A5 JP2005500854 A5 JP 2005500854A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- aiolos
- cell
- oct
- sle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 74
- 101000599042 Homo sapiens Zinc finger protein Aiolos Proteins 0.000 claims description 46
- 102100037798 Zinc finger protein Aiolos Human genes 0.000 claims description 41
- 210000004027 cell Anatomy 0.000 claims description 36
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 29
- 101100295563 Mus musculus Pou2af1 gene Proteins 0.000 claims description 26
- 241000699670 Mus sp. Species 0.000 claims description 23
- 238000000338 in vitro Methods 0.000 claims description 15
- 230000002950 deficient Effects 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 8
- 238000002965 ELISA Methods 0.000 claims description 7
- 210000003734 kidney Anatomy 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 238000009825 accumulation Methods 0.000 claims description 5
- 108010033040 Histones Proteins 0.000 claims description 4
- 101000933607 Homo sapiens Protein BTG3 Proteins 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 239000003226 mitogen Substances 0.000 claims description 3
- 230000003393 splenic effect Effects 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 29
- 238000012360 testing method Methods 0.000 claims 29
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 24
- 208000023275 Autoimmune disease Diseases 0.000 claims 21
- 239000003814 drug Substances 0.000 claims 19
- 229940079593 drug Drugs 0.000 claims 16
- 108700008625 Reporter Genes Proteins 0.000 claims 14
- 241000699666 Mus <mouse, genus> Species 0.000 claims 12
- 150000007523 nucleic acids Chemical class 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 239000012634 fragment Substances 0.000 claims 10
- 239000002773 nucleotide Substances 0.000 claims 10
- 125000003729 nucleotide group Chemical group 0.000 claims 10
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 claims 9
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 claims 9
- 102100035591 POU domain, class 2, transcription factor 2 Human genes 0.000 claims 9
- 101710084411 POU domain, class 2, transcription factor 2 Proteins 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 9
- 238000003556 assay Methods 0.000 claims 7
- 102000004028 Octamer Transcription Factors Human genes 0.000 claims 6
- 108010082496 Octamer Transcription Factors Proteins 0.000 claims 6
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 3
- 238000010240 RT-PCR analysis Methods 0.000 claims 3
- 238000002337 electrophoretic mobility shift assay Methods 0.000 claims 3
- 239000002853 nucleic acid probe Substances 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 claims 2
- 241000233866 Fungi Species 0.000 claims 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 239000004202 carbamide Substances 0.000 claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims 2
- 239000005090 green fluorescent protein Substances 0.000 claims 2
- 230000016507 interphase Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000004611 spectroscopical analysis Methods 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 230000003844 B-cell-activation Effects 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 108091035707 Consensus sequence Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 108060001084 Luciferase Proteins 0.000 claims 1
- 239000005089 Luciferase Substances 0.000 claims 1
- 238000000636 Northern blotting Methods 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000012178 germinal center formation Effects 0.000 claims 1
- 238000012203 high throughput assay Methods 0.000 claims 1
- 230000016178 immune complex formation Effects 0.000 claims 1
- 238000007901 in situ hybridization Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 238000003753 real-time PCR Methods 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 102100026035 Protein BTG3 Human genes 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 102000006947 Histones Human genes 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002583 anti-histone Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0120441.1A GB0120441D0 (en) | 2001-08-22 | 2001-08-22 | Model of autoimmune disease and methods for identifying anti autoimmune disease disorders |
| PCT/EP2002/009365 WO2003018836A2 (en) | 2001-08-22 | 2002-08-21 | Model of autoimmune disease and methods for identifying agents against autoimmune disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005500854A JP2005500854A (ja) | 2005-01-13 |
| JP2005500854A5 true JP2005500854A5 (https=) | 2006-01-05 |
Family
ID=9920835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003523683A Pending JP2005500854A (ja) | 2001-08-22 | 2002-08-21 | 自己免疫疾患に対する薬剤を同定するための、自己免疫疾患のモデルおよび方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20040191756A1 (https=) |
| EP (1) | EP1421218A2 (https=) |
| JP (1) | JP2005500854A (https=) |
| AU (1) | AU2002336999A1 (https=) |
| GB (1) | GB0120441D0 (https=) |
| WO (1) | WO2003018836A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4274856B2 (ja) | 2003-06-19 | 2009-06-10 | オリンパス株式会社 | Ｄｎａとｄｎａ結合タンパク質との反応を検出する方法 |
| EP1589030A1 (en) * | 2004-04-14 | 2005-10-26 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Bob-1 specific T cells and methods to use |
| WO2010054288A2 (en) * | 2008-11-07 | 2010-05-14 | National Jewish Health | Diagnosis and treatment of autoimmune diseases by targeting autoimmune-related b cells ("abcs") |
| WO2012108399A1 (ja) * | 2011-02-10 | 2012-08-16 | 三菱電機株式会社 | 通信システム |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| LT2882441T (lt) | 2012-08-09 | 2020-07-27 | Celgene Corporation | Su imunitetu susijusių ir uždegiminių ligų gydymas |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| US10245266B2 (en) | 2014-05-19 | 2019-04-02 | Celgene Corporation | 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
| US11480568B2 (en) * | 2017-09-28 | 2022-10-25 | Yeda Research And Development Co. Ltd. | Diagnosis of autoimmune diseases |
| US12150973B2 (en) | 2018-05-03 | 2024-11-26 | University Of Utah Research Foundation | OCA-B peptide conjugates and methods of treatment |
| MX2022001664A (es) | 2019-08-09 | 2022-07-19 | Nutcracker Therapeutics Inc | Aparato microfluídico y metodos de uso del mismo. |
| CN116114656B (zh) * | 2022-10-11 | 2024-06-11 | 上海交通大学医学院附属瑞金医院 | 一种红斑狼疮小鼠模型的构建方法及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6890534B1 (en) * | 1995-10-18 | 2005-05-10 | The General Hospital Corporation | Aiolos gene |
| WO1995032284A1 (en) * | 1994-05-24 | 1995-11-30 | Ciba-Geigy Ag | Factor interacting with nuclear proteins |
| EP0856005A4 (en) * | 1995-10-18 | 2001-03-21 | Gen Hospital Corp | THE AIOLOS GEN |
-
2001
- 2001-08-22 GB GBGB0120441.1A patent/GB0120441D0/en not_active Ceased
-
2002
- 2002-08-21 EP EP02772184A patent/EP1421218A2/en not_active Ceased
- 2002-08-21 AU AU2002336999A patent/AU2002336999A1/en not_active Abandoned
- 2002-08-21 US US10/487,116 patent/US20040191756A1/en not_active Abandoned
- 2002-08-21 JP JP2003523683A patent/JP2005500854A/ja active Pending
- 2002-08-21 WO PCT/EP2002/009365 patent/WO2003018836A2/en not_active Ceased
-
2006
- 2006-08-08 US US11/501,626 patent/US20070020673A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wysocki et al. | Current understanding of an emerging role of HLA-DRB1 gene in rheumatoid arthritis–from research to clinical practice | |
| Jacob et al. | Pivotal role of Stat4 and Stat6 in the pathogenesis of the lupus-like disease in the New Zealand mixed 2328 mice | |
| Daly | Pharmacogenomics of adverse drug reactions | |
| Arbore et al. | T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells | |
| Morel et al. | Functional dissection of systemic lupus erythematosus using congenic mouse strains | |
| JP4594588B2 (ja) | 抗体特異的プロファイルの治療的および診断的使用方法 | |
| Yoh et al. | Nrf2-deficient female mice develop lupus-like autoimmune nephritis | |
| Horai et al. | Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist–deficient mice | |
| Gao et al. | Sjögren's syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease | |
| Jiang et al. | Abrogation of lupus nephritis in activation-induced deaminase-deficient MRL/lpr mice | |
| Coffre et al. | Combinatorial control of Th17 and Th1 cell functions by genetic variations in genes associated with the interleukin‐23 signaling pathway in spondyloarthritis | |
| JP2005500854A5 (https=) | ||
| KR20140148459A (ko) | 탈모 질환의 치료 방법 | |
| CN103370076A (zh) | 治疗毛发脱落疾病的方法 | |
| Yip et al. | Gene expression analysis of the pre-diabetic pancreas to identify pathogenic mechanisms and biomarkers of type 1 diabetes | |
| Szántó et al. | Induction of arthritis in HLA–DR4–humanized and HLA–DQ8–humanized mice by human cartilage proteoglycan aggrecan but only in the presence of an appropriate (non‐MHC) genetic background | |
| EP2855516B1 (en) | Inflammation-enabling polypeptides and uses thereof | |
| Rossol et al. | Negative association of the chemokine receptor CCR5 d32 polymorphism with systemic inflammatory response, extra-articular symptoms and joint erosion in rheumatoid arthritis | |
| Forster et al. | p300 protein acetyltransferase activity suppresses systemic lupus erythematosus-like autoimmune disease in mice | |
| Adarichev et al. | Sex effect on clinical and immunologic quantitative trait loci in a murine model of rheumatoid arthritis | |
| US20040191756A1 (en) | Model of autoimmune disease and methods for identifying agents against autoimmune disease | |
| Olofsson et al. | Genetic links between the acute‐phase response and arthritis development in rats | |
| US7172867B2 (en) | Methods of testing for allergic diseases, and therapeutic agents for treating same | |
| Chang et al. | Investigating a pathogenic role for TXNDC5 in rheumatoid arthritis | |
| EP1898698B1 (en) | Non-human mammalian arthritis model featuring human antibodies against citrullinated proteins |